2012.4.19PCR标准化意义(福州).ppt

下载文档 降价啦

0
0
约1.71万字
约 23页
2017-08-20 发布于北京
举报
版权申诉
保障服务

2012.4.19PCR标准化意义(福州).ppt

1、本文档共23页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

* References Branford S, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;(17):2401-2409. Quintas-Cardama A, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113:6315-6321. Muller MC, et al. Molecular Response to First Line Imatinib Therapy is Predictive for Long Term Event Free Surival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV. Blood. 2008;112(11):129. Hughes TP, et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months correlates with long-term outcomes on imatinib (IM) at 72 months: An analysis from the international randomized study of interferon versus STI571 (IRIS) in patients with chronic phase chronic myeloid leukemia (CML-CP). Blood. 2008;112(11):129-130. Press RD, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCY in imatinib mesylate-treated patients with CML. Blood. 2006;107(11):4250-4256. Iacobucci I, et al. Achieving a major molecular response at the time of complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12:3037-3042. Cortes J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with Imatinib Mesylate. Clin Cancer Res. 2005;11:3425-3432. Paschka P, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17:1687-1694. Press RD, et al. A half-log increase in BCR-ABL